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Abstract 25 
The bacterium Providencia stuartii, is associated with urinary tract infections and is the most 26 
common cause of purple urine bag syndrome. The increasing multi-drug resistance pattern shown 27 
by the pathogen and lack of licensed vaccines make treatment of infections caused by P. stuartii 28 
challenging. As vaccinology data against the pathogen is scarce, an in silico proteome based 29 
Reverse Vaccinology (RV) protocol, in combination with subtractive proteomics is introduced in 30 
this work to screen potential vaccine candidates against P. stuartii. The analysis identified three 31 
potential vaccine candidates for designing broad-spectrum and strain-specific peptide vaccines: 32 
FimD4, FimD6, and FimD8. These proteins are essential for pathogen survival, localized in the 33 
outer membrane, virulent, and antigenic in nature. Immunoproteomic tools mapped surface 34 
exposed and non-allergenic 9mer B-cell derived T-cell antigenic epitopes for the proteins. The 35 
epitopes also show stable and rich interactions with the most predominant HLA allele 36 
(DRB1*0101) in the human population. Metabolic pathway annotation of the proteins indicated 37 
that fimbrial biogenesis outer membrane usher protein (FimD6) is the most suitable candidate for 38 
vaccine design, due to its involvement in several significant pathways. These pathways include: 39 
the bacterial secretion system, two-component system, β-lactam resistance, and cationic 40 
antimicrobial peptide pathways. The predicted epitopes may provide a basis for designing a 41 
peptide-based vaccine against P. stuartii.  42 
Keywords: Providencia stuartii; Reverse vaccinology; Subtractive proteomics; Epitopes; 43 
Fimbrial biogenesis outer membrane usher protein. 44 
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1. Introduction 52 
Providencia stuartii is an emerging bacterial pathogen and is the most resistant of all Providencia 53 
species [1]. The pathogen is an etiological agent of complicated urinary tract infections [2], 54 
bacteremia [3], diarrhea [4], meningitis [5], wound infections [6], peritonitis [7], endocardium [8], 55 
conjunctivitis [9], renal abscesses [10], and septicemia [11]. In addition, P. stuartii is the most 56 
common cause of purple urine bag syndrome (PUBS), where purple discoloration of urine occurs 57 
[12]. The pathogen is a urease producer that significantly increases the incidence of urolithiasis 58 
[13]. Antibiotic therapy against P. stuartii is losing its efficacy as the majority of strains are 59 
resistant to several antimicrobial agents, such as: aminopenicillins, first-generation 60 
cephalosporins, fosfomycin, imipenem, polymyxin, penicillin, sulphamethoxazole, tigecycline, 61 
and tetracycline [14-17]. P. stuartii is naturally resistant to colistin and tigecycline, which are 62 
considered as the last-resort treatment for carbapenem-resistant Enterobacteriaceae (CRE) 63 
infections. In other words, there is no appropriate antibiotic available for treatment of carbapenem-64 
resistant P. stuartii [18, 19]. Moreover, in recent years, the emergence of extended-spectrum β-65 
lactamase (ESBL)-producing strains have made this bacterium a focus of great interest as 66 
researchers to attempt find novel routes to tackle this pathogen [14, 15]. 67 
Designing vaccines through a classical vaccinology approach is a challenging task. There are 68 
several limitations associated with this method, including: culturing problems, long duration, 69 
inaccurate and variable products, insufficient attenuation, expensive procedures, less 70 
immunogenicity, and hypersensitivity of the antigens [20]. The availability of genomic 71 
information allows the identification of suitable vaccine proteins in silico without the need to 72 
cultivate the pathogen. A proteome based approach for screening virulent antigens, Reverse 73 
Vaccinology (RV), has received more attention in recent years and has been used for the 74 
identification of vaccine proteins against different pathogens [21, 22, 23, 24, 25]. The RV approach 75 
was first applied to the bacterial pathogen Meningococcus B (MenB)[26], where RV played a 76 
significant role in screening for an antigen with the broadest bactericidal activity and ultimately 77 
resolved the long journey of MenB vaccine development  [25]; [27]. RV has also been applied to 78 
many other bacterial pathogens, including group A Streptococcus [28], antibiotic-resistant 79 
Staphylococcus aureus [27], Streptococcus pneumonia [27], and Chlamydia [27]; [29]. The 80 
efficacy of peptide or subunit based vaccines initially identified through a RV protocol has also 81 
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been proven experimentally [30]. Very recently, a RV approach was used to screen possible 82 
vaccine proteins against Acinetobacter baumannii, identifying outer membrane pilus assembly 83 
protein (FliF), as a strong candidate for vaccine development. In a murine pneumonia model, the 84 
protein FliF was observed experimentally to provide protection of 50 % against lethal doses of 85 
Acinetobacter baumannii [30]. Parameters that are important in the screening of vaccine 86 
candidates include:  outer membrane localization, high virulence, few tran-membrane helices, the 87 
presence of signal peptides, antigenicity, and conservation [21, 22]; [31]. In the current approach, 88 
a RV framework of in silico filters combined with subtractive proteomics was utilized to screen 89 
putative vaccine candidates in the proteome of P. stuartii strain MRSN 2154. The complete 90 
genome of P. stuartii reference strain MRSN 2154 was isolated from an Afghan burn-patient and 91 
sequenced in 2012. The isolate harbors the New Delhi Metallo-β-lactamase-1 gene, which 92 
indicated the presence of numerous other antibiotic resistance loci on the plasmid. It was revealed 93 
that P. stuartii MRSN 2154 has a circular genome of 4,402,109 nucleotides with G/C content of 94 
42%, 4,194 genes, including 4,099 that code for protein, 75 tRNA genes, and 7 rrn operons [32]. 95 
The circular genome of P. stuartii genome can be seen in Fig. 1. The organism proteome was 96 
subtracted to screen out non-paralogs, human-non-homologs, and essential proteins of the 97 
pathogen. The proteins from subtractive proteomics were mapped for their association with unique 98 
pathways of the bacteria. Unique pathways proteins were characterized physicochemically for the 99 
identification of proteins considered feasible for wet lab analysis. The availability of 3D crystal 100 
structures for the filtered proteins was checked and those with no available structure also 101 
underwent a structure prediction and evaluation phase. Protein-protein interactions were explored 102 
for their cellular interacting network to understand the impact of protein inhibition on overall 103 
survival of the pathogen. In the epitope mapping phase, B-cell derived T-cell peptides for the 104 
proteins were predicted [22, 23, 24, 25] and docked into the binding cavity of DRB1*0101 allele 105 
to identify their binding mode and interactions [25]. 106 
 107 
 108 
 109 
 110 
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2. Methodology  111 
The complete flow diagram of the research methodology followed in the manuscript is shown in 112 
Fig. 2. 113 
2.1. Subtractive Proteomics 114 
The process of antigen screening in the pathogen’s proteome starts with subtractive proteomics to 115 
remove proteins with no relevance to the aim of the study. For this, the complete proteome of P. 116 
stuartii reference strain MRSN 2154 (UniProt Id: UP000005012) was retrieved from UniProtKB 117 
[33], which served as input for subtractive proteomics pipeline.  118 
 119 
Fig. 1. Circular genome view of P. stuartii MRSN 2154. 120 
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Initially, paralogous sequences were removed from the genome using the CD-HIT suite 121 
(http://weizhongli-lab.org/cd-hit/) [34]. Paralogous proteins are redundant sequences and arise 122 
because of duplication events during the evolution process [35].These sequences are less 123 
conserved among bacterial species and strains, therefore, not considered as attractive targets for 124 
vaccine design [36]. In the CD-HIT assay, the identity cut-off was set to 0.8 (80%), while the 125 
remaining parameters were treated as default. The non-paralogous (orthologous) sequences were 126 
brought forword to check homology, where sequences were aligned against the human proteome 127 
using protein Basic Local Alignment Search tool (BLASTp) [37] available at the National Center 128 
for Biotechnology Information (NCBI). The E-value cut-off was set to 10-4, while for scoring and 129 
alignment, default parameters were employed. Sequences for which no hit was observed or showed 130 
< 35% identity with the human proteome were filtered out as human non-homologous proteins. 131 
Host homologous proteins were discarded as they generate autoimmune responses [22]. DEG 132 
(database of Essential Genes) (http://www.essentialgene.org/) [38] is a database of genes and 133 
proteins fundamental to organism survival. DEG was used for mining essential proteins from the 134 
set of non-homologous proteins. A BLASTp search was performed with an E-value cut-off of 10-135 
3, bit score of 100, and sequence identity ≥ 30% against the database to filter proteins fulfilling the 136 
threshold values. Essential proteins were targeted as they play a significant role in pathogen’s 137 
survival and any lethal mutation in these can result in the arrest of cell growth [22]. Surface-138 
exposed (exo-proteome) or secreted proteins (secretome) are suitable vaccine targets due to their 139 
frequent contact with the extracellular environment [23]; [39]. In addition, they serve as virulence 140 
factors and increase the pathogen’s ability to adhere, invade, survive, and proliferate within the 141 
host cells [22]; [25]. Therefore, a comparative subcellular localization was performed through 142 
three online tools; PSORTb (http://db.psort.org/) [40], CELLO (http://cello.life.nctu.edu.tw/) [41], 143 
and CELLO2GO (http://cello.life.nctu.edu.tw/cello2go/) [42].  144 
2.2. Identification of Virulent Proteins  145 
Virulent proteins mediate severe infectious pathways in the host and could be attractive targets for 146 
vaccine design [22, 23, 24, 25, 25]; [43]. Several databases are available to predict the virulent 147 
potential of a protein. Two databases were used in the current study:  the Virulence Factor Database 148 
(VFdb) (http://www.mgc.ac.cn/VFs/) [44] and the Microbial Virulence Database (MvirDB) 149 
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(http://mvirdb.llnl.gov/) [45]. A BLASTp search was performed against both the databases to 150 
remove proteins with an identity ≥ 35% and bit score >100%.  151 
2.3. Metabolic Pathways Annotation 152 
Metabolic pathways annotation was performed for the proteins identified as virulent, to shed light 153 
on pathogen pathways crucial for their survival and infectivity [35]. Metabolic pathway analysis 154 
was performed using KAAS (KEGG Automatic Annotation Server) 155 
(http://www.genome.jp/tools/kaas/) [46], maintained by the KEGG (Kyoto Encyclopedia of Genes 156 
and Genomes) database [47].  157 
2.4. Cellular Interactome Analysis 158 
Unveiling the impact of protein-inhibition on the survival of an organism is vital when prioritizing 159 
vaccine proteins [22]; [48]. The STRING (Search Tool for the Retrieval of Interacting 160 
Genes/Proteins) (http://string-db.org/) database was used to disclose the interaction network of the 161 
proteins identified by previous screening stages, at the cellular level [49]. The STRING database 162 
aims to provide a critical assessment and integration of protein-protein interactions, including both 163 
direct (physical) and indirect (functional) associations. Only interactions having an interaction 164 
score of 0.4 were considered. 165 
2.5. Vaccine Protein Prioritization 166 
The virulent proteins identified in the previous screening phase were evaluated for antigenicity 167 
using VaxiJen (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) [50]. The antigenic 168 
potential of proteins is imperative for stimulating the human immune system. Proteins having 169 
VaxiJen score ≥ 0.4 were considered antigenic and prioritized further. Physicochemical 170 
characterization of proteins at the design and development stage is of utmost importance as it aids 171 
subsequent wet lab studies [22, 23, 24, 25]. This was based on several criteria including: molecular 172 
weight, number of transmembrane helices, and adhesion probability. The molecular weight of the 173 
proteins was calculated through ProtParam [51], while numbers of transmembrane helices were 174 
evaluated using the TMHMM (http://www.cbs.dtu.dk/services/TMHMM/) [52] and HMMTOP 175 
(http://www.enzim.hu/hmmtop/) [53] tools. Proteins having molecular weight < 110 kDa are 176 
considered as good targets as such proteins are easy to purify during experimental procedures [22, 177 
8 
 
23, 24, 25]. Knowledge of the numbers of trans-membrane helices is important, as proteins with a 178 
maximum of 2 are more feasible for cloning and expression analysis [22, 23, 24, 25]. Adhesion 179 
probability was finally explored using the Vaxign (http://www.violinet.org/vaxign/) server [54]. 180 
Adhesion proteins aid in bacterial adherence to host tissues and subsequent colonization [55].     181 
2.6. B-cell derived T-cell Epitope Mapping  182 
In epitope mapping, B-cell derived T-cell epitopes for the proteins were predicted. BCPred 183 
(http://ailab.ist.psu.edu/bcpred/predict.html) [56] was used to predict 20-mer B-cell epitopes with 184 
a threshold score > 0.8. The antigenicity of each epitope was further assessed using VaxiJen [50] 185 
and those having antigenic value ≥ 0.4 were analyzed for surface exposure using TMHMM [52]. 186 
For effective vaccine design, the prediction of epitopes that bind to both classes of MHC is 187 
imperative [22, 23, 24, 25]. Binding alleles of the epitopes were determined through Propred1 188 
(http://www.imtech.res.in/raghava/propred1/) [57] and Propred 189 
(http://www.imtech.res.in/raghava/propred/) [58]. T-cell epitopes, which bind to more than 15 190 
MHC alleles, particularly DRB1*0101, were considered [59]. The half maximal inhibition 191 
concentration (IC50) score of the mapped T-cell epitopes was calculated using MHCPred [60] and 192 
those with a score < 100 nM were further analyzed for virulence using VirulentPred [61] with a 193 
cut-off ≥ 0.5.  194 
2.7. Protein and Epitope Allergenicity 195 
It is important to incorporate an allergenicity check in the design framework as an increased 196 
number of vaccines are now reported to cause allergic reactions [62]. Allerdictor 197 
(http://allerdictor.vbi.vt.edu/) [63] was used to predict the allergenicity of the proteins and their 198 
respective epitopes. 199 
2.8. Epitope Conservation and Evolutionary Studies 200 
 In order to design a broad-spectrum and strain-specific vaccine, the predicted epitopes were 201 
inspected for conservation among completely sequenced strains using CLC Sequence Viewer 202 
(www.clcbio.com) [64]. To understand the evolution pattern of P. startuii strains, a 16SrRNA-203 
based evolutionary tree was constructed using MEGA6 [65]. Since a 16SrRNA sequence is subject 204 
to fewer variations, they are often targeted for phylogenetic studies [23]. 205 
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 206 
 207 
Fig. 2. The adopted methodology outlining major activities performed during different phases.208 
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RNAmmer (http://www.cbs.dtu.dk/services/RNAmmer/) [66] was used with default settings for 209 
prediction of 16SrRNA sequence and those with the score of higher than 1700 were subjected to 210 
multiple sequence alignment and phylogenetic tree construction [23]. The multiple sequence 211 
alignment was performed using ClustalW and a phylogenetic tree was constructed based on the 212 
Neighbor-Joining method [67].   213 
2.9. Protein Structure Prediction 214 
In order to visualize the topology of predicted epitopes on the protein surface, the structure of the 215 
proteins was predicted [22, 23, 24, 25]. Proteins with no structural information available in protein 216 
data bank (PDB) [68] were predicted through a comparative structure prediction approach using 217 
the following online tools: Phyre2 [69], SwissModel [70], Intfold2 [71], Modweb [72], and I-218 
Tasser [72]. Each of the predicted structures then underwent structure evaluation analysis through 219 
the following servers: PROCHECK [74], ProSA [75], ERRAT [76], and Verify3D [77]. The 220 
structure with the fewest residues in the disallowed region of a Ramachandran plot and having 221 
most of its residues mapped, was selected and its energy optimized using UCSF Chimera [78]. 222 
Structure minimization was performed for 1500 steps (750 steepest descent and 750 conjugate 223 
gradient with a step size of 0.02 Å) assigning Gasteiger charges under the Tripos Force Field (TFF) 224 
[25]. 225 
2.10. Epitope Topology Prediction 226 
The topology of predicted epitopes was visualized using the Pepitope server 227 
(http://pepitope.tau.ac.il/) [79]. This analysis was vital to gain insights about the 3D structure of 228 
the protein and the epitope’s exomembrane topology [22, 23, 24, 25].  229 
2.11. Molecular Docking  230 
Docking of epitopes with the most common binding allele, DRB1*0101, was performed using 231 
Autodock Vina [80] and GalaxyPepDock server [81]. The 3D structure of the allele was retrieved 232 
from the PDB (PDB ID “1AQD”) and docked with the prioritized epitopes. The peptide-protein 233 
complexes were ranked based on the predicted binding affinity of the peptide in the protein active 234 
site in Autodock Vina.   Results from GalaxyPepDock were assessed based on similarity score, 235 
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estimated accuracy, and interaction score.  The complexes were analyzed for binding mode using 236 
UCSF Chimera [78], and binding interactions using LigPlot [82]. 237 
2.12. Validation through a Positive and Negative Control 238 
The functionality of the framework and validation of the screened vaccine proteins was achieved 239 
using a positive and negative control. The same pipeline was applied to Helicobacter pylori strain 240 
26695 (positive control) [22, 23] and Mycoplasma pneumoniae strain ATCC 15531 (negative 241 
control) for predicting vaccine proteins against them.   242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
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3. Results 258 
3.1. Proteome Subtraction 259 
RV in combination with subtractive proteomics is a hybrid approach that can be explored for 260 
screening of potential peptide-based vaccine candidates in the proteome of bacterial pathogens 261 
[21]. Using this comprehensive approach, we screened antigenic epitopes in the complete 262 
proteome of P. stuartii reference strain MRSN 2154. First, the proteome was filtered through CD-263 
Hit server, which removes paralogous sequences from the proteome. It was revealed by the CD-264 
Hit server that out of total 4220 proteins, 4163 proteins were non-paralogous. Paralogous 265 
sequences are present in the proteome because of duplication events and do not form the core 266 
proteome. Therefore, it was considered logical to remove such sequences due to their 267 
insignificance in the context of vaccine design. To avoid autoimmune reactions, human homologs 268 
were removed from the non-paralogous sequences by performing a BLASTp search against the 269 
human proteome [23]; [37]. This analysis identified 3561 proteins which were subsequently 270 
subjected to DEG analysis [38], revealing 1062 essential proteins. The check for essential proteins  271 
is a key step in the prediction of target proteins, as essential proteins are important factors for the 272 
survival, adhesion, entry into the host, infection, as well as persistence of the pathogen inside the 273 
host [22, 23, 24, 25]. 274 
The identified essential proteins were also examined for subcellular localization using three online 275 
servers: PSORTb [40], CELLO [41], and CELLO2GO [42]. Three servers were used as the 276 
PSORTb server could not predict the localization for some of the proteins. According to PSORTb, 277 
only 1 % of the proteins were found to be located in extracellular regions, 17% were outer 278 
membrane, and 82% were of unknown localization. CELLO indicated as 18% extracellular and 279 
82% as outer-membrane proteins, whilst CELLO2GO predicted 23% to be extracellular and 77% 280 
to be outer membrane proteins. By comparing the results of three tools, 25 proteins were predicted 281 
as outer membranous and one extracellular. Targeting extracellular and outer membrane proteins 282 
is vital, as they can be effective candidates due to their exposure to the extracellular environment 283 
and interaction with their surrounding biotic and abiotic components [22, 23, 24, 25]. In addition, 284 
their role in pathogen virulence, adherence, host cell invasion, and proliferation make them 285 
excellent targets for vaccine design [22, 23, 24, 25].  286 
 287 
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3.2. Virulent Proteins Identification 288 
Extraction of virulent proteins from 25 extracellular and outer membrane proteins was done using 289 
a BLASTp search of VFDB [44] and MvirDB [45] against their core data set. The analysis revealed 290 
13 virulent proteins: FimD1, FimD2, FimD3, FimD4, FimD5, FimD6, FimD7, FimD8, TolC, 291 
OmpF1, OmpF2, TC.OOP, and MepM (Table.1).  292 
Table 1. Virulent proteins of P. stuartii identified through virulent protein analysis. 293 
UniProt ID KEGG Description KEGG Name 
A0A140STA8 Outer membrane usher protein FimD1 
A0A140NFQ5 Outer membrane usher protein FimD2 
A0A140NKU8 Outer membrane usher protein FimD3 
A0A140STH0 Outer membrane usher protein FimD4 
A0A140NJK0 Outer membrane usher protein FimD5 
A0A140NPZ6 Outer membrane usher protein FimD6 
A0A140NJ67 Outer membrane usher protein FimD7 
A0A140NNX3 Outer membrane usher protein FimD8 
A0A140NQ20 Outer membrane protein TolC 
A0A140NKJ2 Outer membrane pore protein F OmpF1 
A0A140NQ63 Outer membrane pore protein F OmpF2 
A0A140NTJ5 OmpA-OmpF porin, OOP family TC.OOP 
A0A140NV54 Murein DD-endopeptidase MepM 
FimD family proteins (FimD1, FimD2, FimD3, FimD4, FimD5, FimD6, FimD7, and FimD8) are 294 
outer membrane molecular usher proteins and play a crucial role in chaperone uncapping and pilus 295 
subunits translocation across the outer membrane during pili assembly [83]. TolC has a role in the 296 
exclusion of diverse molecules such as protein toxins and antibacterial drugs from the cell [84]. 297 
OmpF is a porin protein, which acts as passive diffusion channel for nutrients, small molecules, 298 
toxic salts, and antibiotics [85]. MepM functions in peptidoglycan maturation and recycling as 299 
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well as in cell separation [86]. TC.OOP functions in the process of epithelial invasion and 300 
apoptosis [87]. 301 
3.3. Metabolic Pathway Analysis 302 
The 13 proteins identified by previous rounds of screening were mapped to metabolic pathways 303 
using KAAS. Out of 13 proteins, only 5 proteins were identified as being associated with several 304 
metabolic pathways of the pathogens. These proteins include FimD1, FimD4, FimD6, FUB7, and 305 
FimD8. FimD6 is involved in a bacterial secretion system, two-component system, plant-pathogen 306 
interaction, beta-lactam resistance, and synthesis of cationic antimicrobial peptides. Bacteria have 307 
developed several routes to enter into mammalian host cells, destruct tissue sites, and dampen the 308 
immune system response. One such way is the secretion of proteins across phospholipid 309 
membranes using protein secretion systems and is vital for the survival of bacterial pathogens. The 310 
secreted proteins have many roles in bacterial virulence including attachment, intoxicating, and 311 
subsequent disruption of target cells function. Secretion systems also play a significant role in 312 
scavenging resources in an environmental niche, thus making the host the fittest in the survival 313 
race [88].  Two-component systems facilitate bacteria in signaling events, including cell-cell 314 
communication, adaptation to environments, and pathogenesis [89]. This protein is also involved 315 
in exhibiting resistance to β-lactams, which include penicillin, cephalosporin, carbapenem, and 316 
monobactam [90]. The involvement of FimD6 in several pathways, make it a key target for future 317 
vaccine design (S-Table 1.). 318 
3.4. Protein-Protein Interactions (PPIs) 319 
The five proteins identified in the last step were further evaluated for PPIs within the pathogen 320 
proteome using STRING [49]. Each protein showed ten interacting partners in their protein 321 
network (S-Table 2.). For FimD1, FimD6, and FimD7, the interacting proteins were almost the 322 
same, involved in gram-negative bacteria pili assembly, cell wall organization, and chaperone-323 
mediated protein folding [49]; [83]; [91]. Pili or fimbriae is a virulence factor that helps bacteria 324 
to colonize host specific tissues and enhance its pathogenesis [49]; [91]. In the case of FimD4, 9 325 
interacting proteins were pili proteins while the remaining one was a cell adhesion protein. For 326 
FimD8, 6 proteins were part of cell wall organization, chaperone-mediated protein folding, and 327 
pilus organization, while the other four were involved in cell adhesion [49]. Bacteria need 328 
monomeric adhesions/invasions or highly complicated macromolecular machines such as type III 329 
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secretion systems, and retractile type IV pili to form a complex host-pathogen molecular cross-330 
talk that leads to disruption of cellular functions, and establishment of disease [47].  331 
3.5. Vaccine Protein Prioritization 332 
The five identified proteins were analyzed for antigenicity using VaxiJen. All the five proteins 333 
were found to be antigenic; FimD1 (0.5), FimD4 (0.6), FimD6 (0.5), FimD7 (0.6), and FimD8 334 
(0.5). After confirming them as antigenic, the proteins were subjected to transmembrane helices 335 
analysis using TMHMM [52] and HMMTOP [53]. It was revealed that FimD4 and FimD6 have 336 
one transmembrane helix, whereas candidates FimD1, FimD7 and FimD8have no transmembrane 337 
helices. Computing the number of transmembrane helices was important, as proteins having large 338 
number of transmembrane helices are difficult to clone and express [22, 23, 24, 25]. As all the 339 
proteins have a favorable number of transmembrane helices, they were further analysed for 340 
adhesion probability. The values of adhesion probability for FimD1, FimD4, FimD6, FimD7, and 341 
FimD8 were 0.5, 0.6, 0.5, 0.6, and 0.5, respectively, indicating their adhesive nature. Adhesive 342 
proteins allow bacteria to adhere abiotic surfaces and thus can enhance the pathogenic potential of 343 
the bacteria [25]; [54]; [55]. Furthermore, the proteins were physicochemically characterized 344 
through Protparam [51]. The Grand average of hydropathicity (GRAVY) index value is a measure 345 
of the hydrophobic or hydrophilic nature of a protein. For most proteins, GRAVY values range 346 
from -2 to +2, where negative values indicate a hydrophobic nature. The predicted GRAVY indices 347 
were in the range -0.2 to -0.4, this indicates that they are hydrophilic and nearly all of their residues 348 
are located on the surface, which tends to interact with the host proteins. The instability index of a 349 
protein was predicted by calculating the weighted sum of dipeptides that occur more frequently in 350 
unstable proteins when compared to stable proteins. An instability index greater than 40 indicates 351 
an unstable protein. An instability index of less than 40 was predicted for all the targeted proteins, 352 
indicating that they are stable. The theoretical pI value was less than 7 indicating the acidic nature 353 
of all the 5 selected proteins. The average aliphatic index value for all the proteins denotes high 354 
thermal stability. The molecular weights of the target proteins were calculated. Molecular weight 355 
of the targeted proteins in kDa were as follows: FimD1 (92.1), 93.2 (FimD4), 93.3 (FimD6), 78.3 356 
(FimD7), and 96.8 (FimD8). Low molecular weight (≤ 110 kDa) proteins are considered more 357 
effective targets, as they are easy to purify and are favored during vaccine development (Table 2.) 358 
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[22, 23, 24, 25]. The number of prioritized proteins at each step of the pipeline is presented in the 359 
form of Venn diagram and can be found in (Fig. 3.). 360 
 361 
Fig. 3. Classification of the P. stuartii proteome. A. A representation of the prioritized proteins 362 
selected from the proteome of P. stuartii on the basis of sub-cellular localization, virulence, KEGG 363 
(involvement in metabolic pathways) and antigenic properties. In the Venn diagram, EC 364 
(extracellular) and OM (outer membranous) proteins are  green , virulent proteins are blue, proteins 365 
involved in metabolic pathways (KEGG) are pink, antigenic proteins are yellow and predicted 366 
epitopes are orange. The five prioritized proteins share all the properties (outer membrane, 367 
virulent, involvement in the metabolic pathway and antigenic). B. Shows bar graph for each 368 
category of protein C. The number of shared proteins and specific proteins in each category. 369 
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Table 2. Prioritized vaccine proteins for antigenic epitope mapping. 370 
371 
Protein 
 
Essential 
 
Virulent VaxiJen 
Score 
TMHMM HMMTOP Adhesion       
Probability 
GRAVY Aliphatic 
Index 
Instability 
Index 
Length Theoretical 
pI 
Molecular 
Weight 
FimD1 Yes Yes 0.5 0 0 0.5 -0.4 
 
77.9 
 
25.2 829 6.3 92.1 
FimD4 Yes Yes 0.5 1 1 0.6 -0.2 79.2 35.0 855 6.7 93.2 
FimD6 Yes Yes 0.5 0 1 0.5 -0.3 74.9 29.4 853 6.8 93.3 
FimD7 Yes Yes 0.5 0 0 0.6 -0.4 75.6 32.3 708 6.7 78.3 
FimD8 Yes Yes 0.5 0 1 0.5 -0.4 80.5 26.9 878 5.8 96.8 
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3.6. Mapping of B-cell Derived T-cell Epitopes  372 
Engineering vaccines that can stimulate both humoral and cell-mediated immunity is imperative 373 
in vaccinology [92]. In the current study, we screened epitopes that harbor epitopes of both B-cell 374 
and T-cell, signifying their potential of eliciting both arms of immunity i.e. cellular and humoral 375 
immunity. We identified first B-cell epitopes and then subjected the B-cell epitopes to T-cell 376 
epitope prediction. These B-cell derived T-cell epitopes have the potential to stimulate both types 377 
of immunity. Significantly, these epitopes produced specific and selective immune responses and 378 
avoid many unwanted allergic and reactogenic responses [22, 23, 24, 25]. The proteins found to 379 
have physicochemically favorable properties were, therefore, subjected to a B-cell derived T-cell 380 
epitope prediction phase. First, BCPred [56] was used to predict 20-mer B-cell epitopes for each 381 
of the targeted proteins. The 5 proteins all have between 18 and 22 epitopes [FimD1=20, 382 
FimD4=22, FimD6=18, FimD7=17, FimD8=19].Those epitopes with a BCPred score > 0.8 and a 383 
VaxiJen score > 0.4 [51] were selected for exposed topology analysis using TMHMM [43]. 384 
Surface exposed epitopes were screened for their binding affinity with MHC-class I and MHC-385 
class II molecules. The Propred1 [57] and Propred [58] servers were used to predict binding of 386 
antigenic surface exposed B-cell epitopes to MHC-class I and MHC-class II alleles, especially 387 
DRB1*0101 due to its frequent occurrence. Epitopes that bind to the DRB1*0101 allele tend to 388 
result in good immunogenic responses. Epitopes that bind to more than 15 MHC class I and II 389 
alleles were selected, and evaluated further for IC50 values using MHCPRED [60], antigenicity 390 
through VaxiJen [50], and virulence via VirulentPred [61]. Those epitopes fulfilling all these 391 
criteria were considered. It was found that three epitopes from FimD4 showed binding to more 392 
than 15 MHC classes, of which only  the best epitope ‘FVINDLYPT’ was selected due to its 393 
binding affinity for 51 MHC alleles (including DRB1*0101), antigenicity value of 0.5,   IC50 value 394 
of 4.2, and a virulence score of 1.0. The epitope determined from FimD6 was ‘IQWGNSHSA’  395 
which binds to 38 MHC alleles, has a VaxiJen score of 1.2, an IC50 value of 54.8 and virulence 396 
value of 1.0. Similarly, the ‘YGNANVGYS’ epitope from FimD8 was considered because of its 397 
binding with 54 MHC alleles, antigenicity score of 1.2, IC50 value of 19.9, and virulent value of 398 
1.0 (Table. 3.).   399 
 400 
 401 
 402 
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Table. 3. B-cell derived T-cell epitopes from three prioritized vaccine proteins. 403 
 404 
 405 
Protein B-Cell Epitopes T-Cell Epitopes 
MHC 
Binding 
Alleles 
VaxiJen 
Score  
 
 
VirulentPred MHCPred IC50 Value 
Allidictor Pepitope 
FimD4 APGPFVINDLYPTGTAGDLE FVINDLYPT 51 0.5 1.0 4.2 Non-allergen 
All residues 
exposed 
FimD6 PDSGTLLIQWGNSHSASCGA IQWGNSHSA 38 1.2 1.0 54.8 Non-allergen 
All residues 
exposed 
FimD8 YGNANVGYSYTNDLSQMYYG YGNANVGYS 54 1.2 1.0 19.9 Non-allergen 
All residues 
exposed 
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3.7. Allergenicity Evaluation 406 
A vaccine based on the whole organism or large proteins are not favored due to induction of non-407 
specific immune responses and the reactogenic and/or allergenic responses associated with them. 408 
Such issues can be avoided by designing peptide vaccines based on short peptides capable of 409 
inducing highly targeted immune responses with no reactogenic and/or allergenic responses [93]. 410 
Through the Allerdictor tool [63], it was found that all the three proteins and their epitopes were 411 
non-allergenic. Consequently, these protein epitopes can be considered suitable candidates for 412 
peptide-based vaccine design.  413 
3.8. Conservation and Phylogenetic Analysis 414 
Conservation of epitopes is essential for the design of broad-spectrum vaccines and was thus 415 
included in the design framework. The conservation of the target epitopes was analyzed among 416 
three fully annotated proteomes of P. stuartii using CLC Sequence Viewer. The epitope sequence 417 
‘FVINDLYPT’ from FimD4 and ‘IQWGNSHSA’ from FimD6 were conserved in MRSN 2154 418 
and FDAARGOS_145 strains, but was absent in ATCC 33672 and thus, can be targeted for strain-419 
specific vaccines. The epitope sequence ‘YGNANVGYS’ from FimD8 was predicted to be 420 
conserved in all the 3 strains, an attractive target for a broad-spectrum vaccine (Fig. 4.). To 421 
understand the evolution pattern, a 16SrRNA-based evolutionary tree was constructed using 422 
MEGA6 [65]. The tree illustrated the genetic distances between closely related strains of the 423 
pathogen. It was found that P. stuartii MRSN 2154 and ATCC-33672 fall in the same clade, 424 
showing their phylogenetic closeness, while P. stuartii FDAARGOS_145 is expressed as a 425 
separate branch of the tree, indicating it is phylogenetically distant from the other two strains (Fig. 426 
5.). The close relationship between P. stuartii MRSN 2154 and P. stuartii ATCC 33672 can be 427 
explained based on the genomic information. It was concluded that both the strains have almost 428 
the same genetic contents and can act as model genomes for computational and experimental 429 
studies. As described earlier, P. stuartii MRSN 2154 has a 4,402,109 circular genome, 43% G/C 430 
content and 4,194 predicted genes [32]. Similarly, P. stuartii ATCC 33672 has a 4,285,951-bp 431 
circular genome, 42% GC content, and 4,094 predicted genes [94]. 432 
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 433 
Fig. 4. Alignment and conservation of selected epitopes from FimD4, FimD6 and FimD8 among 434 
three completely annotated strains of P. stuartii. The conserved epitopes are highlighted in red 435 
boxes. 436 
 437 
Fig. 5. The 16SrRNA distance tree representing an evolutionary pattern of P. stuartii strains. 438 
MEGA6 (molecular evolutionary genetic analysis) was used for multiple sequence alignment of 439 
selected 16SrRNA genes through ClustalW and phylogenetic tree construction by the Neighbor-440 
Joining method. The tree has a branch length = 0.00005. The evolutionary distances were 441 
calculated using the maximum composite likelihood method and the branch lengths were measured 442 
in the number of substitutions per site. 443 
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3.9. Prediction and Evaluation of 3D Structures 444 
To view the topology of the predicted epitopes in a subsequent step, the 3D structures of the 445 
proteins were needed. The 3D structures of the proteins were predicted using a comparative 446 
structure prediction approach. To select the optimum model, the evaluation was done for all the 447 
structures predicted using different tools.  The most reliable model was selected by analyzing their 448 
Ramachandran plot generated by PDBSum [74], the Z-score of ProSA [75], the ERRAT quality 449 
score [76], and the Verify3D score [77]. The model generated by Swiss-model [70] was the most 450 
reliable for FimD4 with an ERRAT value of 85.1 and a Verify3D value of 85.2. PDBsum scores 451 
of the model were as follows: 89.5% residues in most favored regions, 9.5 % residues in 452 
additionally allowed regions, 0.60 % residues in generously allowed regions, and 0.4% residues in 453 
disallowed regions, G-factor value of -0.1, and Z–score value of -9.2. Statistically, the structure 454 
possesses 50.8 % of strand, 2.5 % of alpha helix, 4 % of 3-10 helix, and 42.7 % of others (S-Fig. 455 
1.).  The Modweb [72] generated model was selected for FimD6 on the basis of ERRAT value 456 
(59.5), Verify3D value (85.7), residues in most favored regions (87.9 %), residues in additionally 457 
allowed region (10.6 %), residues in generously allowed regions (1.2 %), residues in disallowed 458 
region (0.3 %), G-factor, and Z-score of -0.1 and -9.5, respectively. The secondary structure for 459 
FimD6 depicted that like FimD4, it is made up of more strands than helices. Statistically, the 460 
protein has 50.1 % of strand, 16 % of helix, 2.1 % of 3-10 helix, and 45 % of others (S-Fig. 2.).  461 
Based on the model evaluation results, the model generated by Intfold2 [71] was the best model 462 
for FimD8 with ERRAT value (66.8), Verify3D value (80.6), residues in most favored region (91.0 463 
%), residues in additionally allowed regions (7.8 %), residues in generously allowed regions 464 
(0.70%), residues in disallowed region (0.5%), G-factor value of -0.1 and Z–score value -8.8. (S-465 
Table 3). The minimized structure of the selected models can be found in (Fig. 6.). The secondary 466 
structure of FimD8 also has more B-sheets (47.4 %) compared to alpha helix (1.8 %), 3-10 helix 467 
(3.1 %), and others (47.7 %) (S-Fig. 3.). 468 
3.10. Topology of Epitopes 469 
The topology of antigenic and virulent epitopes was evaluated to ensure their surface exposure 470 
[22, 23, 24, 25]. This analysis is also assured to validate the non-folding of epitopes inside globular 471 
proteins and was performed using Pepitope [79]. This analysis revealed that all the epitopes are 472 
surface exposed (Fig. 7.). The epitope sequence ‘FVINDLYPT’ of FimD4 was located from 473 
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position 320 to 328, ‘IQWGNSHSA’ of FimD6 from 817 to 825 and ‘YGNANVGYS’ of FimD8 474 
from 677 to 685. 475 
 476 
Fig. 6. Minimized structures of the best-predicted structures for prioritized vaccine proteins. 477 
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 478 
Fig. 7. The topology of predicted antigenic epitopes within the 3D structure of the corresponding 479 
proteins. A) FimD4 B) FimD6 C) FimD8.  480 
3.11. Binding Mode and Interaction Analysis 481 
The best peptide-protein complex was selected, and analyzed for binding mode using UCSF 482 
Chimera [78], and binding interactions were identified via Ligplot [82]. In general, the peptides 483 
were found to bind in the same site, with similar interactions predicted by both Autodock Vina and 484 
GalaxyPepDock.  A comparative analysis of peptide docking is shown in Table 4. For all 3 protein-485 
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peptide complexes the binding affinities and scores from GalaxyPepDock are similar. In general, 486 
the complexes predicted by GalaxyPepDock contain more interactions between the protein and the 487 
peptide than the structures predicted by Autodock Vina. The Autodock Vina binding affinity of 488 
the peptide was -9.4 kcal/mol, while GalaxyPepDock, predicts a similarity score of 0.9, an 489 
interaction similarity score of 116.0, and an estimated accuracy of 0.8. In Autodock Vina, 7 490 
hydrogen bonds and 19 hydrophobic interactions were identified, while GalaxyPepDock predicted 491 
8 hydrogen bonds and 21 hydrophobic interactions. Similarly, the FimD6 peptide was found to 492 
bind in the same binding pocket as identified in FimD4. The FimD6 peptide formed multiple 493 
hydrogen bond and hydrophobic interactions with the active site residues. In Autodock Vina, the 494 
peptide formed 7 hydrogen bonds and 13 hydrophobic interactions, while GalaxyPepDock 495 
predicted 9 hydrogen bonds and 17 hydrophobic interactions. The Autodock Vina binding energy 496 
of the peptide was -7.9 kcal.mol and the GalaxyPepDock scores were 0.9 for protein similarity, 497 
114 for the interaction similarity score, and 0.9 for the estimated accuracy. Lastly, the FimD8 498 
peptide has a binding affinity of -8.8 kcal/mol and similarity score of 0.9, interaction similarity 499 
score of 118, and estimated accuracy of 0.9 in GalaxyPepDock. Ligplot analysis revealed 6 500 
hydrogen bonds and 18 hydrophobic interactions for the Autodock Vina structure, while 501 
GalaxyPepDock predicted 6 hydrogen bonds and 16 hydrophobic interactions.    502 
 503 
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Table 4. Comparative analysis of peptide docked complexes interactions in Autodock Vina and GalaxyPepDock. 504 
Receptor Peptide 
Autodock Vina GalaxyPepDock 
Hydrogen 
bonding 
Hydrophobic interactions 
Hydrogen 
bonding 
Hydrophobic interactions 
1AQD 
FVINDLYPT 
(FimD4) 
Gln7, Ser51,  
Tyr58, Trp59, 
Asn60, Arg69, 
Arg74 
Trp7, Leu9, Phe11, Phe20, Phe22, 
Glu26, Ile29, Trp41, Phe52, Glu53, 
Gly56, Trp59, Gln62, Asn67, Ile71, 
Tyr76, His79, Asn80, Val163 
Gln7, Ser51, 
Asn60, Asn67, 
Tyr236, Gln 246, 
Arg247, Asn258 
Glu9, Phe22, Phe30, Ala50, Phe52, 
Glu53, Gly56, Val63, Asp64,  Ile70, 
Leu187, Phe189, Asp233, Gln240, 
Leu243, Ala250, Thr253, Tyr254, 
His257, Val261, Phe265 
1AQD 
IQWGNSHSA 
(FimD6) 
Gln7, Ser51, 
Glu53, Asn60, 
Gln68, Thr75, 
Asn80 
Phe11, Phe22, Glu26, Phe32, Trp41, 
Tyr45, Phe52, Ala57, Gly58, Trp59, 
Val63, Ala72, Tyr78 
Gln7, Arg8, 
Ser51, Glu53, 
Asn60, Asp64, 
Asn67, Arg247, 
Asn258 
Phe22, Ile29, Phe30, Trp41, Ala50, 
Phe52, Gly56, Ala59, Val63, Leu187, 
Phe189, Tyr223, Trp237, Tyr254, 
His257, Val261, Phe265 
1AQD 
YGNANVGYS 
(FimD8) 
Gln7, Ser51, 
Asn60, Asn80, 
Gln68, Arg69 
Ile5, Leu9, Phe11, Phe20, Glu26, 
Cys28, Ile29, Phe30, Trp41, Phe52, 
Gly56, Trp59, Val63, Asp64, Leu65, 
Asn67, Trp76, Gly84 
Gln7, Asn60, 
Trp237, Arg247,   
His257, Asn258. 
Glu9, Phe20, Phe22, Ile29, Phe30, 
Ala50,  Phe52, Gly56, Val63, Asn67, 
Ile70, Phe189, Phe265, Asp233, 
Tyr236, Gln246 
505 
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3.12. Validation through a Positive and Negative control 506 
The pipeline employed in the current work was used to analyze the proteome of H. pylori for 507 
potential vaccine candidates. The pipeline predicted 5 significant potential vaccine proteins against 508 
H. pylori, which includes VacA, babA,sabA, fecA, and Omp16 (S-Table 4.) [22]. Similarly, we 509 
used a negative control to further validate our results. The pipeline revealed no potential vaccine 510 
proteins against M. pneumonia. The CD-hit analysis revealed 606 proteins out of a  total of 629, a 511 
BLASTp search against the human proteome found only 500 proteins as human non-homologous. 512 
Essentiality analysis found 292 proteins as pathogen-essential. Comparative subcellular 513 
localization found 11 proteins as extracellular and cell wall proteins. Only 2 proteins were 514 
predicted to be virulent (MgpC protein and ab uncharacterized extracellular protein). The MgpC 515 
protein has a molecular weight > 110 kDa, and is thus excluded from the list. No T-cell epitopes 516 
were predicted for the uncharacterized extracellular protein, which was consequently also 517 
excluded from the list.     518 
4. Discussion 519 
Progress in sequencing technologies has advanced our understanding regarding the genomic 520 
information of microbial pathogens and opens up new avenues for targeting them [20];[21]. One 521 
route to combat bacterial pathogens is the development of an effective vaccine. The traditional 522 
vaccinology approach introduced by Pasteur has been successfully applied to many pathogens, and 523 
proved fruitful in providing protection against them [95]. However, classical vaccinology 524 
approaches face many obstacles during the development pipeline [22]. The shortcomings of 525 
traditional vaccinology are largely circumvented by integrating in silico filters, which compute 526 
these parameters with accuracy and in less time [22, 23, 24, 25]. Computational vaccinology has 527 
attained great focus in recent years due to it’s user-friendly and straight forward nature [27]. The 528 
lack of a licensed vaccine against P. stuartii demonstrates the need for the development of an 529 
effective peptide-based vaccine. Peptide-based vaccines offer many potential advantages 530 
compared to traditional whole genome based vaccines [93]. They allow the host immune system 531 
to focus solely on a relevant antigenic peptide, thus avoiding the generation of non-protective 532 
responses, immune evasion, and autoimmune responses [58]; [93]. Similarly, peptide based 533 
vaccines are safer and could induce allergen specific tolerance. As peptide-based vaccines are 534 
more favorable and specific in their actions [58], we focused on the identification of antigenic 535 
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epitopes in the proteome of P. stuartii. One of the essential properties of vaccine proteins is 536 
virulence. Virulent proteins tend to initiate infection pathways more efficiently compared to non-537 
virulent proteins [22, 23, 24, 25]. Before screening for virulent proteins, it was critical to discard 538 
those proteins, which were paralogous, host homologous and non-essential, residing in the 539 
cytoplasm or periplasm [25]. Removing host homologous proteins was essential as such proteins 540 
can mediate autoimmune responses due to cross-reactivity with the host proteins [22]. Target 541 
proteins must also be part of pathways essential for the survival of the pathogen. Blocking essential 542 
pathways of the bacteria is lethal for overall survival of the pathogen [25]; [35]. Targeting 543 
extracellular and outer membranous proteins was important, as they can be effective vaccine 544 
candidates due to their role pathogen virulence [22, 23, 24, 25]. Subsequent studies of the proteins 545 
revealed a set of thirteen virulent proteins: FimD1, FimD2, FimD3, FimD4, FimD5, FimD6, 546 
FimD7, FimD8, TolC, OmpF1, OmpF2, TC.OOP and MepM. All these 13 virulent proteins were 547 
human non-homologous, essential for pathogens survival and outer membrane localized. Further 548 
characterization of the targets based on their role in pathogen significant pathways revealed by 549 
KAAS reduced this subset to five proteins. These proteins are associated specifically with unique 550 
pathways of the pathogen (bacterial secretion system, two-component system, plant-pathogen 551 
interaction, β-lactam resistance, cationic antimicrobial peptide, and pili formation) and can be 552 
named as FimD1, FimD4, FimD6, FimD7, and FimD8 [49].  Screening for favorable 553 
physicochemical properties is also important for vaccine design during experimental analysis. The 554 
most critical parameter for a protein to act as vaccine target is their antigenic nature [22]. All the 555 
five proteins from the previous phase were found to be highly antigenic, and thus forwarded to 556 
subsequent analysis. Proteins containing large numbers of transmembrane helices are difficult to 557 
clone and express [22, 23, 24, 25], therefore, proteins with high number of transmembrane helices 558 
were not considered. All the five proteins were found to have one transmembrane helix. The 559 
molecular weight of all the targeted proteins was ≤ 110 kDa and considered due to their easy 560 
purification. The proteins were also found adhesive, which again could increase the virulence of 561 
P. stuartii by adhering and colonizing to host tissues [22, 23, 24, 25]. 562 
Mapping of B-cell derived T-cell epitopes for antigenic proteins is a critical step while designing 563 
vaccines [22, 23, 24, 25]. Only three epitopes: FVINDLYPT, IQWGNSHSA and YGNANVGYS 564 
from FimD4, FimD6 and FimD8 were considered, due to their higher binding affinity for MHC 565 
molecules, higher antigenic, virulence score, and low IC50 value. The proposed epitopes were all 566 
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identified as non-allergenic and conserved in strains of P. stuartii, important for designing a broad-567 
spectrum vaccine [25]. These conserved regions evolve slowly and are subject to less variability, 568 
therefore, targeting such epitopes are reliable in the context of peptide-based vaccine design [24, 569 
25]. The epitope sequence ‘FVINDLYPT’ (320-328) of FimD4 and ‘IQWGNSHSA’ (817-825) of 570 
FimD6 was conserved in 67%, thus can be used for designing strain-specific vaccines while 571 
epitope sequence ‘YGNANVGYS’ of FimD8 (677-685) was predicted to be conserved in all the 572 
3 strains (100% conservation), a protein target for broad-spectrum vaccine design [25]. 573 
Furthermore, pepitope analysis of all the three epitopes revealed their surface exposed topology, 574 
which again favored them as suitable vaccine candidates. Molecular docking and complex 575 
analysis,  showed the deep binding of the epitopes in the binding cavity of the receptor allele, 576 
making multiple hydrogen bonds and hydrophobic interactions with active site residues. The 577 
formation of multiple hydrogen bonds indicates the stability of the docked complex. Lastly, the 578 
pipeline was validated through a positive (H.pylori) and negative (M. pneumoniae) control. Studies 579 
on immune protective efficacy of vacA in small and large animal models revealed that this protein 580 
could induce local gastric T cell (Th1 and Th17) responses [22, 23]. In addition to vacA, the current 581 
pipeline predicted 4 other proteins (babA, fecA omp16, and sabA), which could serve as potential 582 
vaccine candidates against H. pylori.  The M. pneumoniae study revealed no proteins that could 583 
serve as potential candidate. This was obvious as M. pneumonia lacks a cell wall and has very few 584 
cell surface proteins. The only two proteins, MgpC protein and uncharacterized extracellular 585 
protein, were found to have high molecular weight and did not bear any B-cell derived T-cell 586 
epitope, therefore, were not considered. Thus, we are confident in the predictions made by the 587 
designed pipeline.  Despite of the many advantages of predicting antigenic peptides in bacterial 588 
proteomes, there remains several obstacles to effective vaccine development. These obstacles 589 
include: the low intrinsic immunogenicity of individual peptides, optimal delivery routes, the task 590 
of combining different antigenic peptides to properly engage cellular and humoral immunity, and 591 
poor population coverage of T-cell epitopes. Moreover, the prediction of B-cell epitopes are 592 
notoriously unreliable [25]; [93]. As there is a scarcity of antigenic epitopes against the pathogen, 593 
we believe that outcomes of this study will help experimental vaccinology in designing vaccine 594 
against this emerging bacterial pathogen and reducing the emergence and dissemination of its 595 
resistance strains. 596 
 597 
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Conclusions 598 
Antimicrobial resistance by bacterial pathogens is a serious concern around the globe. Due to the 599 
slow pace of antibiotic development and the rapid pace of resistance acquisition, there is an urgent 600 
need for effective vaccines against these bacterial pathogens.  In this context, we have identified 601 
novel potential vaccine candidates against P. stuartii. The proteins (FimD4, FimD6, and FimD8) 602 
are host non-homologous, essential, and part of P. stuartii exoproteome and secretome. Metabolic 603 
pathway mapping and the cellular interactome of the proteins indicated their pivotal role in the 604 
establishment of infection and its progression. B-cell derived T-cell epitopes were mapped 605 
successfully for the proteins, and found to be highly conserved and virulent. Furthermore, the 606 
antigenic epitopes demonstrated high affinity for the catalytic cavity of DRB1*0101, signifying 607 
that the epitopes could generate the desired response. These targets could be useful in designing 608 
broad-spectrum and strain-specific vaccines against virulent and multidrug-resistant clones of the 609 
pathogen. 610 
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